Roden Richard, Wu T-C
Department of Pathology, The Johns Hopkins University, Baltimore, Maryland 21231, USA.
Nat Rev Cancer. 2006 Oct;6(10):753-63. doi: 10.1038/nrc1973.
Cancer of the uterine cervix is the second largest cause of cancer deaths in women, and its toll is greatest in populations that lack screening programmes to detect precursor lesions. Persistent infection with 'high risk' genotypes of human papillomavirus (HPV) is necessary, although not sufficient, to cause cervical carcinoma. Therefore, HPV vaccination provides an opportunity to profoundly affect cervical cancer incidence worldwide. A recently licensed HPV subunit vaccine protects women from a high proportion of precursor lesions of cervical carcinoma and most genital warts. Here we examine the ramifications and remaining questions that surround preventive HPV vaccines.
子宫颈癌是女性癌症死亡的第二大原因，在缺乏检测癌前病变筛查计划的人群中，其造成的死亡人数最多。人乳头瘤病毒（HPV）“高危”基因型的持续感染是导致宫颈癌的必要条件，尽管并非充分条件。因此，HPV疫苗接种为深刻影响全球宫颈癌发病率提供了一个契机。一种最近获得许可的HPV亚单位疫苗可使女性预防大部分宫颈癌前病变和大多数尖锐湿疣。在此，我们探讨围绕预防性HPV疫苗的影响及尚存的问题。
